Atorvastatin calcium is a HMG CoA reductase inhibitor. Mainly through inhibiting the synthesis of HMGCoA reductase, thus inhibiting the synthesis of cholesterol in vivo, reducing the content of serum low density lipoprotein cholesterol and triglyceride. Atorvastatin calcium can inhibit the synthesis of cholesterol, interfere with the production of lipoprotein, reduce the level of serum total cholesterol, effectively reduce the level of serum triglyceride, but also increase the level of serum high-density lipoprotein cholesterol. It can reduce the plasma LDL-C level in some homozygous familial hypercholesterolemia patients, but this type of population has little response to other lipid-lowering drugs. It is clinically used for primary hypercholesterolemia, mixed hyperlipidemia, hypertriglyceridemia, homozygous familial hypercholesterolemia and prevention and treatment of atherosclerosis.